Today Amplia announced that it has reached a significant milestone, with the Phase 1b portion of the ongoing ACCENT clinical trial now complete.
The Phase 1b portion of the trial investigated the safety and tolerability of narmafotinib (AMP945), the Company’s lead asset and best-in-class FAK inhibitor, in combination with standard-of-care chemotherapy gemcitabine and nab-paclitaxel (Abraxane®) in first-line pancreatic patients.
Following a review of clinical trial data by the ACCENT Safety Review Committee, we have now identified a dose of narmafotinib that is both safe and well tolerated, which means the Phase 2a (Part B) portion of the trial can begin.
Amplia’s CEO and Managing Director Dr Chris Burns commented:
“Completion of the Phase 1b stage of the trial is an important milestone for the ACCENT trial. We have now identified a safe and well-tolerated dose of narmafotinib to take into the Phase 2a stage of the trial and the preliminary efficacy signals we have seen to date, across three dose cohorts, are very encouraging. The team at Amplia is now focused on executing the next phase of the trial as quickly and efficiently as possible.”
Click here to read today’s ASX release.
